Clinical trials located in

Bydgoszcz

Bydgoszcz city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Bydgoszcz, located in northern Poland, is a city rich in history and culture. Founded in the 11th century, it boasts a unique architectural blend, with its Granaries on the Brda River being iconic landmarks. The city is renowned for its music scene, home to the Pomeranian Philharmonic and the Bydgoszcz Opera Festival. Bydgoszcz also plays a pivotal role in Poland’s water sports, thanks to its well-developed rowing and canoeing facilities. The Bydgoszcz Canal, a marvel of 19th-century engineering, enhances its picturesque landscape.

  • CT-EU-00121743

    Study comparing Giredestrant and Fulvestrant with CDK4/6 Inhibitors for advanced breast cancer

    This study focuses on a type of advanced breast cancer known as Estrogen Receptor-Positive (ER+), HER2-Negative breast cancer. This kind of cancer is driven by hormones and does not have high levels of the HER2 protein. The study aims to evaluate the effectiveness and safety of a new drug called Giredestrant compared to an existing drug called Fulvestrant. Both drugs will be combined with one of three medicines that inhibit proteins in cancer cells called CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib).

    In this study, participants will be randomly assigned to one of two groups. One group will receive Giredestrant and the other will receive Fulvestrant. Both groups will also receive one of the CDK4/6 inhibitors chosen by their doctor. These combinations are being tested to see which works better to stop the cancer from growing or spreading.

    The drugs involved include Giredestrant (RO7197597, RG6171, GDC-9545), Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, and LHRH Agonist (for pre/perimenopausal women and men).

    The goal is to find out if Giredestrant can provide better results and fewer side effects compared to Fulvestrant when both are combined with one of the CDK4/6 inhibitors. The study may involve regular tests and assessments to monitor the cancer’s progress and the patient’s response to the treatment.

    Participants will continue to receive the study drugs as long as they are benefiting from them and not experiencing unacceptable side effects. The study involves close monitoring to ensure the safety and well-being of all participants throughout the treatment period.

    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • CT-EU-00068643

    Study of the effects and safety of Inavolisib and Fulvestrant compared with Alpelisib and Fulvestrant in patients with advanced breast cancer

    The clinical trial is for breast cancer. Its aim is to evaluate the effectiveness and safety of the drug combination inavolisib and fulvestrant compared with the drug combination alpelisib and fulvestrant.

    It is aimed at patients with locally advanced or metastatic breast cancer. All patients who will participate in the study have previously undergone therapy based on cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and hormonal therapy. Study participants’ breast cancer must be hormone receptor positive (HR+), human epidermal growth factor receptor type 2 negative (HER2-), and must have a PIK3CA gene mutation.

    The aim of the study is to compare which drug combination – inavolisib and fulvestrant or alpelisib and fulvestrant – is more effective in the treatment of this type of breast cancer. This study also tries to assess what the side effects of both therapies are.

    Inavolisib and fulvestrant treatment involves administering inavolisib tablets once a day and fulvestrant injections at the beginning and during treatment cycles. An alternative treatment, i.e. alpelisib with fulvestrant, also involves daily use of alpelisib tablets and fulvestrant injections according to planned cycles.

    • Alpelisib
    • Fulvestrant
    • Inavolisib
  • Study of Tobemstomig and supportive medications for patients with advanced or metastatic triple-negative breast cancer

    The clinical trial is for patients with triple-negative breast cancer (TNBC) that is locally advanced, inoperable or metastatic (stage IV) and has not been previously treated. The study compares a new immune therapy, Tobemstomig (RO7247669), in combination with Nab-Paclitaxel, and Pembrolizumab.

    The aim of the study is to assess the effectiveness and safety of the therapy. Patients will be randomly assigned to one of two groups: in the first group, patients will receive Tobemstomig every three weeks and Nab-Paclitaxel for three weeks, followed by a week off. In the second group, patients will receive Pembrolizumab every three weeks and Nab-Paclitaxel for three weeks, followed by a week off. Therapies will be continued until disease progression or for a maximum of 24 months from the start of treatment.

    The study is aimed at adults aged 18 and over who are well enough to be eligible for treatment. The presence of appropriate markers in the tumor tissue is also required. Patients cannot participate in the study if they have ongoing infections, uncontrolled health problems, or are pregnant.

    • Tobemstomig
    • Pembrolizumab
    • nab-Paclitaxel
  • Evaluating a dual anticoagulant therapy for patients with atrial fibrillation and acute coronary syndrome after percutaneous coronary intervention

    This study focuses on patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) who have undergone a procedure called percutaneous coronary intervention (PCI). The therapy being tested involves a combination of drugs to prevent blood clots and manage heart health after PCI.

    Patients with both AF and ACS face a challenge: preventing clots while avoiding excessive bleeding. Standard practice often includes three drugs: an oral anticoagulant (OAC) to prevent stroke, aspirin, and clopidogrel. However, using all three drugs together can lead to a high risk of bleeding within a year.

    The study aims to find out if using just two drugs—dabigatran and ticagrelor—can be as safe and effective as the standard three-drug therapy. This approach is called a dual anticoagulant regimen. Participants in the study will be men and women aged 18 and older who have nonvalvular AF and have successfully undergone PCI for ACS. They will be randomly assigned to one of two groups: one group will receive dabigatran and ticagrelor, while the other group will receive dabigatran, clopidogrel, and aspirin. The treatment will last for 12 months.

    The main goal of the study is to see if the dual therapy is as good as the triple therapy in preventing major bleeding and cardiovascular events like heart attacks and strokes. The study also looks at other outcomes, such as death and the need for additional heart procedures. This research will provide important information about a new treatment strategy that could improve safety and effectiveness for patients with AF and ACS who undergo PCI.

    • Ticagrelor
    • clopidogrel
    • Dabigatran
    • Aspirin
  • Study assessing the effectiveness of Tebentafusp administered alone and in combination with Pembrolizumab in the treatment of advanced melanoma

    The aim of this study is to test new treatments for people with advanced skin melanoma that does not respond well to other therapies. The main focus was on a new experimental drug called tebentafusp, which is a special type of protein that helps the body’s immune system recognize and attack cancer cells.

    The study divided patients into three different groups. One group will receive tebentafusp alone. Another group will receive tebentafusp in combination with another immunotherapy drug called pembrolizumab. The third group will receive the treatment that the doctor thinks is best for the patient – this could be another experimental drug, standard therapy, or simply supportive care.

    Scientists are primarily focusing on the effectiveness of these treatments in shrinking tumors and extending patient survival. They will also monitor closely for any side effects to make sure the treatment is safe. The study is expected to last about two years and will include frequent check-ins to monitor patient responses.

    • Tebentafusp
    • Pembrolizumab
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    • mRNA-4157/V940
    • placebo
    • Pembrolizumab
  • Efficacy and safety study of rosnilimab in moderate to severe rheumatoid arthritis

    This study will evaluate the effectiveness and safety of Rosnilimab in patients with moderate to severe rheumatoid arthritis. Rosnilimab is an antibody that activates the PD-1 receptor, also known as ANB030. Patients will be randomly assigned to receive Rosnilimab or placebo.

    The main aim of the study is to assess changes in the 28-Joint Disease Activity Index based on the concentration of C-reactive protein (DAS28-CRP) after 12 weeks of treatment. DAS28-CRP is a validated tool that assesses disease activity based on the number of painful and swollen joints and the concentration of C-reactive protein in the blood. A reduction in DAS28-CRP indicates an improvement in the patient’s condition.

    This study aims to test whether Rosnilimab is effective and safe in the treatment of rheumatoid arthritis. If the results are promising, this drug could become a new treatment option for patients suffering from this disease.

    • placebo
    • Rosnilimab
  • Study of the safety of Imvotamab in the treatment of rheumatoid arthritis

    This test is for people with moderate or severe rheumatoid arthritis who has not improved with previous treatment. The main goal is to test the safety and tolerance of the body to a new drug called Imvotamab.

    In this study, participants will receive Imvotamab or a placebo directly into their veins. A placebo looks like a drug but contains no active drug. This method helps to understand the effects of Imvotamab by comparing it with a placebo. The study was carefully designed to monitor the effects of the drug, including any side effects and side effects that participants may experience. Of particular interest is the body’s response to the drug and the behavior of the drug in the body over time.

    This study is being conducted at multiple sites and involves approximately 24 participants. Each participant will participate in the study for a maximum of 52 weeks. During this time, their health and any changes in symptoms of rheumatoid arthritis will be closely monitored.

    Participating in this study could potentially provide new insight into an individual’s condition and contribute to the development of new treatments for rheumatoid arthritis. Participation in the study is voluntary, and all necessary information will be provided to enable you to make an informed decision about joining the study.

    • Imvotamab
    • placebo
  • Study of the effectiveness of CPL409116 in the treatment of rheumatoid arthritis

    A clinical trial is being presented that focuses on evaluating the efficacy and safety of a new drug called CPL409116 in individuals with active rheumatoid arthritis (RA) who have not achieved improvement with methotrexate alone. The study is designed to last for 12 weeks and aims to enroll approximately 100 participants, who will be divided into four groups. Each group will receive different doses of CPL409116 or a placebo, in addition to their continued methotrexate treatment.

    CPL409116 is a promising drug that works by targeting specific pathways in the body known to contribute to inflammation and RA symptoms. By inhibiting these pathways, CPL409116 could potentially reduce disease activity and improve symptoms. The main objective of this study is to determine how well CPL409116 can decrease disease activity compared to a placebo, which will be measured using the DAS28(CRP) score. This score takes into account the number of swollen or tender joints, the level of a specific protein in the blood that indicates inflammation, and how the patient assesses their disease activity.

    Participants in this study will be randomly assigned to one of the treatment groups and will take the study drug or placebo twice daily for 85 consecutive days. It is important for participants to have been on a stable dose of methotrexate for at least 12 weeks prior to joining the study, with no dosage changes for at least 8 weeks before the study begins.

    This study aims not only to evaluate the efficacy of CPL409116 but also its safety, ensuring that it is well-tolerated by participants. If someone is struggling with active rheumatoid arthritis and has not achieved an adequate response to methotrexate, this study may provide an opportunity to access a potentially new treatment option while contributing to significant research that could benefit other individuals with RA in the future.

    • CPL409116
    • placebo
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    • aflibercept
    • OPT-302
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    • BIIB122
  • A comprehensive evaluation of retatrutide in obesity and associated comorbidities

    This study evaluates the effectiveness and safety of a new drug, retatrutide, in individuals with obesity or overweight, including those with knee osteoarthritis or obstructive sleep apnea. Lasting about 89 weeks, the trial involves randomized assignment of participants to either receive retatrutide or a placebo. The main goals are to observe changes in body weight, knee pain in osteoarthritis, and sleep apnea severity. The study also examines various secondary outcomes like changes in BMI, waist circumference, and blood pressure. The trial aims to provide new insights into weight management and associated health conditions, offering hope for improved treatments.

    • Retatrutide
  • Understanding biliary tract cancer treatment with rilvegostomig and chemotherapy

    This study focuses on a new treatment for biliary tract cancer using the drug rilvegostomig combined with chemotherapy. It is for patients who have had surgery to remove this cancer. The study will compare the effectiveness of rilvegostomig with a placebo in combination with investigator’s choice of chemotherapy options like capecitabine, gemcitabine/cisplatin, or S-1. The main aim is to see if this new treatment can prevent cancer from coming back. About 750 people will take part in this global study, which is in the final phase of testing.

    • Gimeracil
    • Oteracil
    • Tegafur
    • Gemcitabine
    • Cisplatin
    • Rilvegostomig
    • Capecitabine
  • Macitentan and selexipag in ongoing pulmonary hypertension care

    This study is for people with a lung disease called pulmonary hypertension (PH) who have taken part in a previous study and are receiving specific treatment. The main goal of the study is to enable these people to continue treatment even after the previous study has ended. The study involves monotherapy with Macitentan or Selexipag and a combination of Macitentan and Tadalafil at fixed doses. All of these drugs are administered orally. The aim of the study is to check how safe the treatment is when used long-term. Will be monitored if any adverse events occur. If this leads to discontinuation of treatment, this will be reported.

    • Selexipag
    • Macitentan/Tadalafil FDC
    • macitentan
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    • Vibostolimab
    • Pembrolizumab
  • Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    • gefurulimab/ALXN1720
  • A study on the effect of zanamivir in babies with influenza

    This study tests the medicine zanamivir in hospitalized babies under 6 months with severe flu. It’s an open-label trial, meaning everyone knows they’re getting zanamivir. The medicine is given through an IV for up to 10 days. Researchers will check how the medicine moves in the body, its safety, and how it affects flu symptoms. Babies will be followed for 24 days, including after the treatment ends. The aim is to understand if zanamivir can safely help very young babies with serious flu.

    • Zanamivir
  • CT-EU-00041922

    Testing new medication for adult muscle inflammation treatment

    This study aims to test a medicine called Efgartigimod (EFG PH20 SC) for adults who are suffering from a disease called Idiopathic Inflammatory Myopathy (IIM), where muscles become inflamed for unknown reasons. This condition often falls into groups like dermatomyositis, immune-mediated necrotizing myopathy, or specific types of polymyositis. The trial wants to compare how good the medicine is against a placebo. The researchers will look at how much people’s symptoms improve and whether there are any side effects. The test is going to be carried out in many locations and will involve people over 18 years old.

    • Efgartigimod/ EFG PH20 SC
  • Testing new combination treatments for kidney cancer

    This study, part of a broader research project exploring new treatments for kidney cancer, specifically Renal Cell Carcinoma (RCC). These treatments include different combinations of drugs from among the listed: Pembrolizumab, Favezelimab, Belzutifan, Lenvatinib, Quavonlimab and Vibostolimab. The research comprises two stages: a safety assessment stage and an efficacy evaluation stage. In the first stage, the study aims to determine the safety and tolerability of a few different drug combinations. The study will monitor any unexpected adverse health events and track the number of participants who may need to discontinue the treatment due to health concerns. In the second stage, the study will assess the effectiveness of these various drug combinations and identify any uncomfortable or unwelcome effects. Additionally, researchers will observe how many participants can continue the treatment without experiencing adverse effects.

    • Vibostolimab
    • Quavonlimab
    • Pembrolizumab
    • Favezelimab
    • Lenvatinib
    • Belzutifan

See more clinical trials in other cities in Poland:

.